PHARMANUTRA SPA (PHN.MI) Stock Fundamental Analysis

BIT:PHN • IT0005274094

67 EUR
+2 (+3.08%)
Last: Feb 27, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to PHN. PHN was compared to 15 industry peers in the Personal Care Products industry. PHN gets an excellent profitability rating and is at the same time showing great financial health properties. While showing a medium growth rate, PHN is valued expensive at the moment. With these ratings, PHN could be worth investigating further for quality investing!.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year PHN was profitable.
  • PHN had a positive operating cash flow in the past year.
  • Each year in the past 5 years PHN has been profitable.
  • PHN had a positive operating cash flow in each of the past 5 years.
PHN.MI Yearly Net Income VS EBIT VS OCF VS FCFPHN.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

1.2 Ratios

  • PHN has a Return On Assets of 20.17%. This is amongst the best in the industry. PHN outperforms 100.00% of its industry peers.
  • Looking at the Return On Equity, with a value of 36.55%, PHN belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
  • The Return On Invested Capital of PHN (25.72%) is better than 100.00% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for PHN is significantly above the industry average of 11.43%.
  • The 3 year average ROIC (17.21%) for PHN is below the current ROIC(25.72%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 20.17%
ROE 36.55%
ROIC 25.72%
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
PHN.MI Yearly ROA, ROE, ROICPHN.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

1.3 Margins

  • Looking at the Profit Margin, with a value of 13.39%, PHN is in the better half of the industry, outperforming 68.75% of the companies in the same industry.
  • In the last couple of years the Profit Margin of PHN has declined.
  • The Operating Margin of PHN (21.79%) is better than 100.00% of its industry peers.
  • In the last couple of years the Operating Margin of PHN has remained more or less at the same level.
  • Looking at the Gross Margin, with a value of 97.13%, PHN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • PHN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 21.79%
PM (TTM) 13.39%
GM 97.13%
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
PHN.MI Yearly Profit, Operating, Gross MarginsPHN.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • PHN has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • PHN has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, PHN has less shares outstanding
  • The debt/assets ratio for PHN has been reduced compared to a year ago.
PHN.MI Yearly Shares OutstandingPHN.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
PHN.MI Yearly Total Debt VS Total AssetsPHN.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 11.03 indicates that PHN is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 11.03, PHN belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • PHN has a debt to FCF ratio of 2.01. This is a good value and a sign of high solvency as PHN would need 2.01 years to pay back of all of its debts.
  • PHN has a better Debt to FCF ratio (2.01) than 68.75% of its industry peers.
  • A Debt/Equity ratio of 0.24 indicates that PHN is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.24, PHN is in the better half of the industry, outperforming 62.50% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF 2.01
Altman-Z 11.03
ROIC/WACC3.24
WACC7.93%
PHN.MI Yearly LT Debt VS Equity VS FCFPHN.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

  • PHN has a Current Ratio of 2.19. This indicates that PHN is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of PHN (2.19) is better than 87.50% of its industry peers.
  • A Quick Ratio of 1.86 indicates that PHN should not have too much problems paying its short term obligations.
  • PHN has a better Quick ratio (1.86) than 93.75% of its industry peers.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 1.86
PHN.MI Yearly Current Assets VS Current LiabilitesPHN.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • PHN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.84%, which is quite good.
  • PHN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 14.63% yearly.
  • PHN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.35%.
  • The Revenue has been growing by 16.59% on average over the past years. This is quite good.
EPS 1Y (TTM)12.84%
EPS 3Y6.71%
EPS 5Y14.63%
EPS Q2Q%13.11%
Revenue 1Y (TTM)14.35%
Revenue growth 3Y19.25%
Revenue growth 5Y16.59%
Sales Q2Q%19.45%

3.2 Future

  • PHN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.13% yearly.
  • Based on estimates for the next years, PHN will show a quite strong growth in Revenue. The Revenue will grow by 13.74% on average per year.
EPS Next Y6.25%
EPS Next 2Y13.31%
EPS Next 3Y15.13%
EPS Next 5YN/A
Revenue Next Year14.94%
Revenue Next 2Y14.86%
Revenue Next 3Y14.87%
Revenue Next 5Y13.74%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
PHN.MI Yearly Revenue VS EstimatesPHN.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
PHN.MI Yearly EPS VS EstimatesPHN.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2 2.5

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 26.69 indicates a quite expensive valuation of PHN.
  • The rest of the industry has a similar Price/Earnings ratio as PHN.
  • The average S&P500 Price/Earnings ratio is at 27.07. PHN is around the same levels.
  • Based on the Price/Forward Earnings ratio of 27.43, the valuation of PHN can be described as expensive.
  • Based on the Price/Forward Earnings ratio, PHN is valued a bit more expensive than the industry average as 62.50% of the companies are valued more cheaply.
  • The average S&P500 Price/Forward Earnings ratio is at 28.05. PHN is around the same levels.
Industry RankSector Rank
PE 26.69
Fwd PE 27.43
PHN.MI Price Earnings VS Forward Price EarningsPHN.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PHN is valued a bit more expensive than 62.50% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHN indicates a slightly more expensive valuation: PHN is more expensive than 75.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 62.22
EV/EBITDA 14.93
PHN.MI Per share dataPHN.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The excellent profitability rating of PHN may justify a higher PE ratio.
  • A more expensive valuation may be justified as PHN's earnings are expected to grow with 15.13% in the coming years.
PEG (NY)4.27
PEG (5Y)1.82
EPS Next 2Y13.31%
EPS Next 3Y15.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. Dividend

5.1 Amount

  • PHN has a Yearly Dividend Yield of 1.53%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 1.77, PHN pays a bit more dividend than its industry peers.
  • PHN's Dividend Yield is comparable with the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 1.53%

5.2 History

  • On average, the dividend of PHN grows each year by 11.21%, which is quite nice.
Dividend Growth(5Y)11.21%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • PHN pays out 39.70% of its income as dividend. This is a sustainable payout ratio.
  • The dividend of PHN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP39.7%
EPS Next 2Y13.31%
EPS Next 3Y15.13%
PHN.MI Yearly Income VS Free CF VS DividendPHN.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M
PHN.MI Dividend Payout.PHN.MI Dividend Payout, showing the Payout Ratio.PHN.MI Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

PHARMANUTRA SPA

BIT:PHN (2/27/2026, 7:00:00 PM)

67

+2 (+3.08%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)11-10
Earnings (Next)03-13
Inst Owners17.49%
Inst Owner ChangeN/A
Ins Owners65.02%
Ins Owner ChangeN/A
Market Cap648.56M
Revenue(TTM)180.41M
Net Income(TTM)24.16M
Analysts82.86
Price Target83.98 (25.34%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.53%
Yearly Dividend0.85
Dividend Growth(5Y)11.21%
DP39.7%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.65%
PT rev (3m)1.65%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0.72%
Revenue NQ rev (1m)2.53%
Revenue NQ rev (3m)2.53%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)0.77%
Valuation
Industry RankSector Rank
PE 26.69
Fwd PE 27.43
P/S 3.59
P/FCF 62.22
P/OCF 44.89
P/B 9.81
P/tB 15.54
EV/EBITDA 14.93
EPS(TTM)2.51
EY3.75%
EPS(NY)2.44
Fwd EY3.65%
FCF(TTM)1.08
FCFY1.61%
OCF(TTM)1.49
OCFY2.23%
SpS18.64
BVpS6.83
TBVpS4.31
PEG (NY)4.27
PEG (5Y)1.82
Graham Number19.64
Profitability
Industry RankSector Rank
ROA 20.17%
ROE 36.55%
ROCE 44.34%
ROIC 25.72%
ROICexc 34.17%
ROICexgc 53.82%
OM 21.79%
PM (TTM) 13.39%
GM 97.13%
FCFM 5.78%
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
ROICexc(3y)25.61%
ROICexc(5y)33.67%
ROICexgc(3y)43.23%
ROICexgc(5y)50.61%
ROCE(3y)29.76%
ROCE(5y)31.61%
ROICexgc growth 3Y-15.98%
ROICexgc growth 5Y-10.26%
ROICexc growth 3Y-20.69%
ROICexc growth 5Y-11.75%
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
F-Score7
Asset Turnover1.51
Health
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF 2.01
Debt/EBITDA 0.37
Cap/Depr 112.59%
Cap/Sales 2.23%
Interest Coverage 250
Cash Conversion 33.69%
Profit Quality 43.15%
Current Ratio 2.19
Quick Ratio 1.86
Altman-Z 11.03
F-Score7
WACC7.93%
ROIC/WACC3.24
Cap/Depr(3y)763.09%
Cap/Depr(5y)544.05%
Cap/Sales(3y)14.97%
Cap/Sales(5y)11.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.84%
EPS 3Y6.71%
EPS 5Y14.63%
EPS Q2Q%13.11%
EPS Next Y6.25%
EPS Next 2Y13.31%
EPS Next 3Y15.13%
EPS Next 5YN/A
Revenue 1Y (TTM)14.35%
Revenue growth 3Y19.25%
Revenue growth 5Y16.59%
Sales Q2Q%19.45%
Revenue Next Year14.94%
Revenue Next 2Y14.86%
Revenue Next 3Y14.87%
Revenue Next 5Y13.74%
EBIT growth 1Y10.97%
EBIT growth 3Y13.47%
EBIT growth 5Y17.77%
EBIT Next Year22.37%
EBIT Next 3Y20.23%
EBIT Next 5Y9.65%
FCF growth 1Y164.53%
FCF growth 3Y1.75%
FCF growth 5Y17.94%
OCF growth 1Y18.84%
OCF growth 3Y0.14%
OCF growth 5Y11.34%

PHARMANUTRA SPA / PHN.MI FAQ

What is the fundamental rating for PHN stock?

ChartMill assigns a fundamental rating of 7 / 10 to PHN.MI.


Can you provide the valuation status for PHARMANUTRA SPA?

ChartMill assigns a valuation rating of 2 / 10 to PHARMANUTRA SPA (PHN.MI). This can be considered as Overvalued.


What is the profitability of PHN stock?

PHARMANUTRA SPA (PHN.MI) has a profitability rating of 9 / 10.


How financially healthy is PHARMANUTRA SPA?

The financial health rating of PHARMANUTRA SPA (PHN.MI) is 8 / 10.


Is the dividend of PHARMANUTRA SPA sustainable?

The dividend rating of PHARMANUTRA SPA (PHN.MI) is 6 / 10 and the dividend payout ratio is 39.7%.